Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is on our list of the top 10 stocks under $5 that could triple.

Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program

As of March 17, 2026, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) remains a preferred choice among analysts, with Wedbush increasing the price target to $14 from $13 and reiterating an “Outperform” rating on the company’s shares. The firm reflected optimism surrounding the company’s clinical pipeline and upcoming catalysts.

As its focus remains on precision oncology, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)’s recent progress in the silevertinib program has supported the company’s share price performance.

Wedbush analysts noted that, in December 2025,  the company had already reported preliminary Phase 2 data on silevertinib in NSCLC patients with uncommon EGFR mutations. The program is moving forward, and further data readouts are expected in the coming months, which remains a key catalyst.

On March 16, 2026, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported financial results for the fourth quarter and full year ended December 31, 2025. The company cited its 60% objective response rate, 86% CNS ORR, and 91% disease control rate from the previously released Phase 2 data, as well as the upcoming developments, which include the future data presentations and the initiation of a randomized Phase 2 GBM trial in Q2 2026. In terms of finances, cash reserves have increased to $128.7 million, net income has risen to $22.4 million, and the company’s runway is expected to extend into the second half of 2028.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations, with a focus on brain-penetrant EGFR inhibitors for NSCLC and glioblastoma.

While we acknowledge the risk and potential of BDTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BDTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.